Dr. Daniel M. Geynisman, M.D.
Medical Oncology (Medical Oncology Physician)
- Medicare participating
At a glance
- Medical school
- University of Pittsburgh School of Medicine (2006)
- Years since graduation
- 20
- In the NPI registry since
- 2007
- Medicare patients seen, 2024
- 235
The NPI date is when this clinician registered for a National Provider Identifier, the billing number used on health claims. It is not a license, graduation or board-certification date. NPIs were first issued in May 2005 and became required on claims in 2007–2008, so an early date usually means the clinician was already in practice before then. What an NPI is
Education and training
- 2006Medical school: University of Pittsburgh School of Medicine
- 2007Registered with an NPI (national billing number; not a license date) — NPIs began in 2005, so practice likely started earlier
Undergraduate school, residency, fellowship, licensing exams and board certification aren’t in public federal data. Board certification can be confirmed with the certifying board (ABMS member boards for MDs, AOA boards for DOs).
Specialties and state licenses
-
Medical Oncology Physician primary
PA license MD436806 - Student in an Organized Health Care Education/Training Program
As reported to the NPI registry. To confirm a license is current, check the state medical board.
Where they work
Hospitals
- Hospital of Univ of Pennsylvania Philadelphia, PA
- Chester County Hospital West Chester, PA
- Temple University Hospital Philadelphia, PA
- Bayhealth Medical Center, Kent Campus Dover, DE
Medical groups
- Temple Faculty Practice Plan Inc (1,368 clinicians)
Hospitals this clinician lists with Medicare, and groups they bill Medicare through (Care Compare). Affiliation doesn’t mean they see patients at every location.
Medicare patients and services
- Medicare patients, 2024
- 235
- Services billed
- 663
- Patients’ average age
- 76
| Service | Times | Patients |
|---|---|---|
| Established patient office or other outpatient visit, 30-39 minutes | 399 | 195 |
| Established patient office or other outpatient visit, 40-54 minutes | 210 | 108 |
| Established patient office or other outpatient visit, 20-29 minutes | 28 | 25 |
| New patient office or other outpatient visit, 60-74 minutes | 22 | 22 |
| New patient office or other outpatient visit, 45-59 minutes | 20 | 20 |
Medicare fee-for-service only. CMS leaves out services billed for fewer than 11 patients. These figures describe a practice’s Medicare work; they aren’t a measure of quality.
Medicare prescriptions
| Drug | Prescriptions |
|---|---|
| Abiraterone Acetate | 347 |
| Prednisone Other prescribers in Philadelphia, PA | 335 |
| Xtandi (enzalutamide) | 184 |
| Orgovyx (relugolix) | 143 |
| Nubeqa (darolutamide) | 107 |
| Inlyta (axitinib) | 53 |
| Cabometyx (cabozantinib s-malate) | 41 |
| Erleada (apalutamide) | 39 |
| Oxycodone Hcl Other prescribers in Philadelphia, PA | 32 |
| Amlodipine Besylate Other prescribers in Philadelphia, PA | 32 |
Prescriptions filled under Medicare Part D, including refills. CMS leaves out drugs prescribed fewer than 11 times.
Payments from drug and device companies
In 2025, 12 companies reported 34 payments worth $17,516 in total to this clinician.
| Exelixis Inc. | $13,613 |
|---|---|
| Avyxa Pharma, LLC | $3,426 |
| Pfizer Inc. | $116 |
| Taiho Oncology, Inc. | $75.38 |
| Daiichi Sankyo Inc. | $68.46 |
| AstraZeneca Pharmaceuticals LP | $65.70 |
| Gilead Sciences, Inc. | $37.78 |
| Merck Sharp & Dohme LLC | $27.71 |
| Consulting Fee | $11,220 |
|---|---|
| Compensation for services other than consulting (speaking, faculty) | $2,000 |
| Honoraria | $1,980 |
| Travel and Lodging | $1,338 |
| Food and Beverage | $936 |
| Speaking at a medical education program | $41.66 |
What the payments were for
| Company | What it was for | Amount |
|---|---|---|
| Exelixis Inc. Sep 4, 2025 | Consulting Fee CABOMETYX · Renal Cell Carcinoma (RCC) Hepatocellular Carcinoma (HCC) Differentiated Thyroid | $7,920 |
| Exelixis Inc. Nov 13, 2025 | Consulting Fee CABOMETYX · Renal Cell Carcinoma (RCC) Hepatocellular Carcinoma (HCC) Differentiated Thyroid | $3,300 |
| Avyxa Pharma, LLC Sep 13, 2025 | Compensation for services other than consulting (speaking, faculty) | $2,000 |
| Exelixis Inc. Nov 20, 2025 | Honoraria CABOMETYX · Renal Cell Carcinoma (RCC) Hepatocellular Carcinoma (HCC) Differentiated Thyroid | $1,980 |
| Avyxa Pharma, LLC Sep 13, 2025 | Travel and Lodging travel to MIAMI BEACH, FL · in-kind | $648 |
| Avyxa Pharma, LLC Sep 13, 2025 | Travel and Lodging travel to MIAMI BEACH, FL · in-kind | $591 |
| Taiho Oncology, Inc. Jan 22, 2025 | Travel and Lodging travel to Orlando, FL · in-kind | $35.91 |
| Taiho Oncology, Inc. Apr 30, 2025 | Speaking at a medical education program | $24.80 |
| AstraZeneca Pharmaceuticals LP Jan 22, 2025 | Travel and Lodging travel to Orlando, FL · in-kind | $24.42 |
| AstraZeneca Pharmaceuticals LP Jan 22, 2025 | Travel and Lodging travel to Orlando, FL · in-kind | $24.42 |
All 12 payments other than meals, newest first
| Company | What it was for | Amount |
|---|---|---|
| Exelixis Inc. Nov 20, 2025 | Honoraria CABOMETYX · Renal Cell Carcinoma (RCC) Hepatocellular Carcinoma (HCC) Differentiated Thyroid | $1,980 |
| Exelixis Inc. Nov 13, 2025 | Consulting Fee CABOMETYX · Renal Cell Carcinoma (RCC) Hepatocellular Carcinoma (HCC) Differentiated Thyroid | $3,300 |
| Avyxa Pharma, LLC Sep 13, 2025 | Compensation for services other than consulting (speaking, faculty) | $2,000 |
| Avyxa Pharma, LLC Sep 13, 2025 | Travel and Lodging travel to MIAMI BEACH, FL · in-kind | $648 |
| Avyxa Pharma, LLC Sep 13, 2025 | Travel and Lodging travel to MIAMI BEACH, FL · in-kind | $591 |
| Exelixis Inc. Sep 4, 2025 | Consulting Fee CABOMETYX · Renal Cell Carcinoma (RCC) Hepatocellular Carcinoma (HCC) Differentiated Thyroid | $7,920 |
| Taiho Oncology, Inc. Apr 30, 2025 | Speaking at a medical education program | $24.80 |
| AstraZeneca Pharmaceuticals LP Apr 30, 2025 | Speaking at a medical education program | $16.86 |
| Taiho Oncology, Inc. Apr 30, 2025 | Travel and Lodging travel to Orlando, FL | $14.67 |
| Taiho Oncology, Inc. Jan 22, 2025 | Travel and Lodging travel to Orlando, FL · in-kind | $35.91 |
| AstraZeneca Pharmaceuticals LP Jan 22, 2025 | Travel and Lodging travel to Orlando, FL · in-kind | $24.42 |
| AstraZeneca Pharmaceuticals LP Jan 22, 2025 | Travel and Lodging travel to Orlando, FL · in-kind | $24.42 |
Each payment as the company reported it, with the products it named. Meals are counted in the totals above but not listed one by one.
From CMS Open Payments. A payment is not evidence of wrongdoing; many are for consulting, teaching or meals. Clinicians can review and dispute their records with CMS.
Industry-funded research
Named as a principal investigator on 9 industry-funded studies in 2025, from 7 companies. The companies reported $841,899 in research payments for these studies, mostly to the institutions running them.
- A Trial to Find Out if REGN4336 is Safe and How Well it Works Alone and in Combination With REGN5678 for Adult Participants With Advanced Prostate Cancer
Regeneron Pharmaceuticals, Inc. · Recruiting · NCT05125016 - A Phase 1/2 Open-Label, Dose-Escalation and Cohort Expansion Clinical Trial to Evaluate the Safety, Tolerability, Pharmacokinetics, and Pharmacodynamics of ARV-766 Monotherapy and in Combination With Abiraterone in Pa…
Novartis Pharmaceuticals Corporation - An Open-Label, Randomized Phase 3 Study to Evaluate Enfortumab Vedotin vs Chemotherapy in Subjects With Previously Treated Locally Advanced or Metastatic Urothelial Cancer (EV-301)
Astellas Pharma Global Development - A Phase 2, Single-arm, Open-label Clinical Trial of Pembrolizumab Plus Lenvatinib in Participants with First-line Advanced,Metastatic Non-clear Cell Renal Cell Carcinoma nccRCC KEYNOTE-B61
Merck Sharp & Dohme LLC - A Phase 3, Open-label, Multicenter, Randomized Study of Xaluritamig vs Cabazitaxel or Second Androgen Receptor-Directed Therapy in Subjects With Metastatic Castration-Resistant Prostate Cancer Previously Treated With …
Amgen Inc. - A study of enfortumab vedotin ASG22CE as monotherapy or in combination with other anticancer therapies for the treatment of urothelial cancer
Pfizer Inc. - A Phase II, Randomized, Open-label, Multi-center Study of JSB462 (Luxdegalutamide) in Combination With Abiraterone in Adult Male Patients With Metastatic Hormone-sensitive Prostate Cancer (mHSPC)
Novartis Pharmaceuticals Corporation - A Phase II Clinical Trial to Study the Efficacy and Safety of Pembrolizumab MK-3475 and Pembrolizumab in Combination with Other Investigational Agents in Subjects with High-risk Non-muscle-Invasive Bladder Cancer NMIB…
Merck Sharp & Dohme LLC - A Phase III Double-Blind Randomised Placebo-Controlled Study Assessing the Efficacy and Safety of Capivasertib + Docetaxel Versus Placebo + Docetaxel as Treatment for Patients with Metastatic Castration Resistant Pros…
AstraZeneca UK Limited
From CMS Open Payments research payments, where companies name up to five principal investigators per payment. Research payments usually go to hospitals, universities and research sites, not to the investigator personally. A payment is not evidence of wrongdoing.